Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Data readout from Phase 3 clinical trial in the People's Republic of China evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical trial...

Related Keywords

United States ,Beijing ,China ,Japan ,Atago ,Japan General ,San Diego ,California ,Chan Ying ,Yunnan ,Stephen Jasper ,Rodneyl Nussbaum ,Preclinical Development Updates ,National Reimbursement Drug List ,Audit Committee ,Clinical Development Updates ,Exchange Commission ,Catalyst Biosciences Inc ,Company Board Of Directors ,Arthur Andersen ,Continent Pharmaceuticals Co Ltd ,Gyre Therapeutics Inc ,Gyre Pharmaceuticals ,Ernst Young ,Gyre Pharmaceuticals Co Ltd ,Group Ltd ,National Medical Products Administration ,Gc Biopharma Corp ,Chief Executive ,Chief Executive Officer ,Gyre Pharmaceutical Phase ,Asia Pacific ,Managing Executive ,Atago Advisory ,Senior Partner ,Asia Pacific Region ,Chief Operating Officer ,Base Therapeutics ,Chief Technology Officer ,Tactiva Therapeutics ,Catalyst Biosciences ,Gyre Therapeutics ,Ishak Scoring System ,Full Year Ended December ,Marketing Expense ,Western High Fat Diet ,Breakthrough Therapy ,Drug Evaluation ,Private Securities Litigation Reform Act ,Annual Report ,Definitive Proxy Statement ,Ended December ,Preferred Stock ,Markets ,